Tuesday, November 09, 2021 4:08:46 PM
I may be wrong, but most often those who make estimated tax payments do so based on the previous years tax liability. The IRS won't charge a penalty if you pay at least 100% of the tax liability of your previous years tax (making estd payments in 2022 based on 2021 tax) or if you pay at least 90% of your current years tax(2022).
ex. Your 2021 tax liability is $25,000 and your 2022 tax liability ends up being $30,000. In order to escape penalties and interest, you would need to have paid estimated taxes of 100% of the previous years $25,000 or, if you're brave enough to venture an educated guess, you'd need to have paid in 80% of the 2022 liability or $24.000.
Most choose the 100% route as it's much easier to calculate.
So, a capital gain put off until January 2022 would most certainly delay your payment of taxes.
Just my take,
rum
ex. Your 2021 tax liability is $25,000 and your 2022 tax liability ends up being $30,000. In order to escape penalties and interest, you would need to have paid estimated taxes of 100% of the previous years $25,000 or, if you're brave enough to venture an educated guess, you'd need to have paid in 80% of the 2022 liability or $24.000.
Most choose the 100% route as it's much easier to calculate.
So, a capital gain put off until January 2022 would most certainly delay your payment of taxes.
Just my take,
rum
Recent AUPH News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/03/2026 08:56:49 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:19:38 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:19:18 PM
- Kezar Life Sciences shares surge after Aurinia announces acquisition • IH Market News • 03/30/2026 03:07:34 PM
- Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right • Business Wire • 03/30/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/23/2026 12:03:47 PM
- Aurinia Announces Management Transition • Business Wire • 03/23/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/10/2026 08:25:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 09:14:36 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 11:06:24 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 11:02:50 AM
- Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress • Business Wire • 02/26/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2026 09:08:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2026 09:05:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2026 09:04:33 PM
- Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026 • Business Wire • 02/19/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 09:49:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2026 09:12:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2026 09:11:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/04/2025 01:00:47 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/04/2025 11:06:12 AM
- Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress • Business Wire • 11/04/2025 11:00:00 AM
- Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025 • Business Wire • 11/03/2025 11:00:00 AM
- Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025 • Business Wire • 10/15/2025 10:00:00 AM
- Aurinia Responds to Now Retracted LinkedIn Post • Business Wire • 09/30/2025 12:27:00 AM
